1. Introduction {#sec1}
===============

The multistage process of carcinogenesis involves the progressive acquisition of mutations and epigenetic abnormalities in the expression of multiple genes, with an important group among them being those involved in cell cycle control \[[@B1]\].

The orderly progression of the cells through the various phases of cell cycle, namely, G1, S, G2, and M phases is precisely governed by a series of proteins called "cyclins," which exert their effect by binding and activating the cyclin-dependent kinases (CDK) \[[@B2]\].

Cyclin D1, a 45 kD (kilo Dalton) protein encoded by cyclin D1 gene (CCND1) located on chromosome 11q13, is a part of the molecular system that regulates the cell cycle G1 to S transition \[[@B2]\]. It was first isolated as Parathyroid adenomatosis 1 gene (PRAD1) oncogene clonally rearranged and overexpressed in parathyroid adenomas and is identical to B-cell lymphoma1 gene (bcl-1) protoncogene, which is translocated and overexpressed in a subset of B-cell neoplasms \[[@B1]\].

Overexpression of cyclin D1 leads to shortening of G1 phase and less dependency on growth factors resulting in abnormal cell proliferation which in turn might favour the occurrence of additional genetic lesions \[[@B1]\].

Cyclin D1 expression has been studied in various carcinomas including oral squamous cell carcinomas. Some studies have been carried out to correlate the expression of cyclin D1 with histological grading of this neoplasm \[[@B2]--[@B5]\]. However, the results have not been consistent and conclusive.

Hence, this retrospective laboratory-based study was undertaken to study the expression of cyclin D1 in oral squamous cell carcinoma and to correlate its expression with histological differentiation.

2. Materials and Methods {#sec2}
========================

Forty formalin-fixed paraffin-embedded (FFPE) tissue blocks of incisional biopsy specimens, which were histologically diagnosed as oral squamous cell carcinoma (OSCC), were retrieved from the archives of Department of Oral and Maxillofacial Pathology of the Pacific Dental College, Udaipur, India. One FFPE tissue block of normal oral mucosa was included as a positive control and one squamous cell carcinoma tissue with exclusion of primary antibody was used as negative control.

From each FFPE tissue block, 3-4 *μ* thick sections were cut and stained by H&E stain for histopathological grading. Tumours were graded according to Broder\'s criteria \[[@B6]\] into well- (WDSCC; *n* = 13), moderately (MDSCC; *n* = 16), and poorly differentiated (PDSCC; *n* = 11) ones.

Immunohistochemical study was carried out using polymer-labelling technique (Dako, Envision). Sections were dewaxed, washed in alcohol and antigen retrieval was carried out in a Decloaking Chamber (Pascal) with 10 mM Citra solution at 125°C for 30 seconds followed by 90°C for 10 seconds. Slides were cooled naturally and brought to room temperature. Slides were placed inside the Dako Autostainer Universal Staining System, an automated immunohistochemistry staining system. Endogenous peroxidase was blocked by using 0.3% hydrogen peroxide in methanol at room temperature for 10 minutes. Slides were washed with phosphate-buffered saline (PBS) briefly and incubated with primary antibody (Cyclin D1) for 60 minutes. Section were again washed with PBS, incubated with the polymer for 30 minutes, and washed again with PBS. Diaminobenzidine (DAB) was used as the chromogen in hydrogen peroxide for 10 minutes. Sections were then counterstained with haemotoxylin, mounted, and studied under light microscope for immunorecativity.

Presence of brown-coloured end product at the site of target antigen was indicative of positive immunoreactivity. The negative control demonstrated the absence of staining. Tissue section of positive control showed brown staining of the cells of basal and parabasal layers and was confirmed as being positively stained ([Figure 1](#fig1){ref-type="fig"}). The evaluation of study cases was done subsequently in a similar way for IHC reactivity. Only the slides showing positive reactivity were further evaluated for cyclin D1 expression as per criteria described by Gu et al. \[[@B7]\].

In every slide ten, hot spot areas were selected and observed under higher (400X) magnification with a grid. Percentage of IHC positive tumour cells per hot spot was calculated and the mean percentage per slide (labelling index) was determined ([Figure 2](#fig2){ref-type="fig"}). A labelling index score of 1, 2, 3, or 4 was assigned for labelling indices 1--25%, 26--50%, 51--75%, and \>75%, respectively.

The intensity of cyclin D1 immunostaining ([Figure 3](#fig3){ref-type="fig"}) was evaluated on the basis of microscopic appearance as weak, intermediate, or strong and an intensity score of 1, 2, or 3 was assigned to them, respectively.

A final expression score was calculated by multiplying labelling index score with intensity score, based on which the cyclin D1 expression was determined as weak (score 1--4), moderate (score 5--8), or strong (score 9--12).

All the relevant clinical, histopatholocal, and immunohistochemical data so obtained were tabulated and subjected to appropriate statistical analysis using the SPSS 11 statistical software.

3. Results {#sec3}
==========

Cyclin D1 positivity was seen in 18 cases (45%) of OSCC. Further distribution of cyclin D1 reactivity in accordance with site, clinical stage, and histopathological differentiation are explained in [Table 1](#tab1){ref-type="table"}. The labelling index scores, intensity of staining, expressions graded, and their correlations with clinical and histological parameters are elaborated in Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}.

Both cyclin D1 reactivity and expression did not show any correlation with site and clinical staging of the OSCC (Tables [1](#tab1){ref-type="table"} and [3](#tab3){ref-type="table"}). The histopathological differentiation showed a positive correlation with increase in both the reactivity and expression with increasing differentiation (Tables [1](#tab1){ref-type="table"} and [3](#tab3){ref-type="table"}). The labelling index score and intensity did not correlate with OSCC differentiation ([Table 2](#tab2){ref-type="table"}).

4. Discussion {#sec4}
=============

The present study was carried out to study the immunohistochemical reactivity and expression of cyclin D1 and its association with site, clinical staging, and histopathological differentiation of oral squamous cell carcinoma.

The IHC reactivity for cyclin D1 was evaluated on the basis of presence or absence of brown staining. Nuclear and cytoplasmic stainings in all the cases of positivity were observed, which was similar to other studies \[[@B3], [@B4], [@B7]--[@B19]\]. However, Gillett et al. \[[@B20]\] considered only cytoplasmic staining as negative, and Vora et al. \[[@B5]\] reported exclusively cytoplasmic staining in their cases and considered the same as positive.

De Falco et al. have stated that in adult tissues, cyclin D1 plays a role in proliferation and differentiation and the shift between nucleus and cytoplasm is necessary to regulate finely the passage across different phases of the cell cycle. The immunogold observations have indicated transit of cyclin D1 between nuclear and cytoplasmic compartments via nuclear pores \[[@B17]\].

In the present study, cyclin D1 reactivity was seen in 45% of cases. Some authors have reported less than 45% reactivity \[[@B4], [@B8], [@B9], [@B13]--[@B16], [@B21]\] while some have shown more \[[@B2], [@B3], [@B5], [@B10], [@B12], [@B16], [@B22]--[@B25]\]. These reported variations in reactivity may be due to diverse reasons like asymmetric labelling expression seen in different parts of same specimen owing to the fact that in a specimen at a given time, only about 20% of the neoplastic cells are under mitosis \[[@B8]\]. A discrepancy in staining between the biopsy and surgical resection materials has also been reported, most likely owing to tissue heterogeneity \[[@B26]\]. Further, cyclin D1 has been described to express itself mainly in the peripheral layers of tumour islands and not in the cells exhibiting mitosis \[[@B3]\]. The pRb gene also appears to regulate transcription of the cyclin D1 which is destabilized in pRb-negative cells and hence cells negative for pRb staining do not express cyclin D1; this may be due to the fact that sometimes cyclin D1 acts as a negative regulator of cell cycle progression \[[@B20]\]. Bartkova et al. reported that in several common solid tumours, cyclin D1 protein may be essential for G1 phase progression while some may have lost thier requirement \[[@B27]\]. Further, an inverse relationship of HPV status has also been reported with cyclin D1 expression in OSCC \[[@B18]\].

To determine the cyclin D1 expression, we used a more objective and inclusive method, as depicted by Gu et al. \[[@B7]\] by multiplying the intensity score with labelling index score. Whereas a few authors have used only a subjective evaluation of intensity at three point criteria as "weak, moderate, and strong" \[[@B2], [@B4], [@B28]\] or two point criteria as "weak and strong" \[[@B21], [@B29]\] and considered it as final expression. While some other investigators have used labelling index score only as final expression \[[@B3], [@B5], [@B9], [@B10], [@B12], [@B14]--[@B16], [@B21], [@B23], [@B24], [@B30]\]. Maahs et al. used stereologic method to determine labelling index \[[@B8]\].

In our study, the labelling index did not have any correlation with histopathological differentiation and the results could not be compared directly with other reported literatures, because of different criteria used for determining scores by different authors \[[@B3], [@B5], [@B9], [@B10], [@B12], [@B14]--[@B16], [@B21], [@B23], [@B24], [@B30]\].

The staining intensity was nonuniform, showing maximum cases of intermediate staining followed by weak and strong. Angadi and Krishnapillai \[[@B2]\] and Mishra and Das \[[@B4]\] noted a uniformly increasing intensity in relation to the histopathological differentiation, whereas Castle et al. \[[@B28]\] found no correlation.

In the present study, the cyclin D1 expression shown by maximum number of cases was weak, followed by strong, and intermediate. The expression had a significant correlation with histological differentiation. There was an increase in cyclin D1 expression with increasing differentiation, that is, highest expression was seen in WDSCC, followed by MDSCC, and PDSCC. Since no studies on OSCC are available in the literature using the similar criteria for determining expression as used in the present study, we cannot directly compare this data with that of others.

Many studies have been done on cyclin D1 in OSCC, and even though the controversy exists in the scientific literature, it opens a window of opportunity for further discussion and research in different tumours with additional different criteria like lymph node involvement and metastasis. The interpretation of the above study is precluded by its limited sample size and therefore the study should be followed further with large sample size to validate our finding. The observations in this field may contribute significantly to the patient well-being and decreased morbidity and mortality by establishing cyclin D1 as a better prognostic marker.

![Photomicrograph depicting Cyclin D1 expression in basal and suprabasal layers of normal epithelium.](TSWJ2012-978327.001){#fig1}

![Photomicrograph depicting labelling index calculation under high magnification with a grid.](TSWJ2012-978327.002){#fig2}

![Photomicrograph depicting intensity evaluation under high magnification.](TSWJ2012-978327.003){#fig3}

###### 

Distribution of site, clinical staging, histopathological differentiation of OSCC, and their IHC reactivity.

  ------------------------------------------------------------------------------------------
  Distribution category               Total number   IHC reactivity                
  ----------------------------------- -------------- ---------------- ---- ------- ---------
  Site                                                                             0.282\
                                                                                   NS

   Alveolus                           11             07               04   63.63   

   Buccal mucosa                      13             05               08   38.46   

   Tongue                             15             05               10   33.33   

   Lip                                01             01               00   100     

                                                                                   

  Clinical staging                                                                 0.867\
                                                                                   NS

   Stage I                            06             03               03   50      

   Stage II                           07             04               03   57.14   

   Stage III                          13             05               08   38.4    

   Stage IV                           14             06               08   42.8    

                                                                                   

  Histopathological differentiation                                                

   WDSCC                              13             09               04   69.23   0.011 S

   MDSCC                              16             08               08   50      

   PDSCC                              11             01               10   9.09    

                                                                                   

  OSCC (total)                        40             18               22   45      
  ------------------------------------------------------------------------------------------

###### 

Labelling index score, and intensity in relation to histopathological differentiation.

  OSCC differentiation   Intensity   Labelling index score                               
  ---------------------- ----------- ----------------------- --- ------- --- --- --- --- -------
  WDSCC                  4           3                       2   0.075   1   5   3   0   0.361
  MDSCC                  2           4                       2   (NS)    1   1   6   0   (NS)
  PDSCC                  0           0                       1   0       0   0   1       
                                                                                         
  OSCC                   6           7                       5           2   6   9   1   

###### 

Cyclin D1 expression in relation to site, clinical staging, and histopathological distribution.

  Distribution category               Cyclin D1 expression             
  ----------------------------------- ---------------------- ---- ---- ----------
  Site                                                                 0.255 NS
   Alveolus                           04                     01   02   
   Buccal mucosa                      01                     02   02   
   Tongue                             04                     00   01   
   Lip                                00                     01   00   
                                                                       
  Clinical Staging                                                     0.866 NS
   Stage I                            01                     01   01   
   Stage II                           03                     01   00   
   Stage III                          02                     01   02   
   Stage IV                           03                     01   02   
                                                                       
  Histopathological differentiation                                    
   WDSCC                              07                     00   02   0.042 S
   MDSCC                              02                     04   02   
   PDSCC                              00                     00   01   
                                                                       
  OSCC (total)                        09                     04   05   
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